Home

David F Burgstahler

CIK 1374179 · President and CEO · last filed 2023-01-30

David F Burgstahler is a President and CEO who has filed 41 SEC Form 4 insider transactions across 11 companies since 2007. Across all open-market trades the lifetime net is −$123.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $103.6M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$103.60M

Companies

11

Total Filings

41

Lifetime Open-Market Net

-$123.20M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
RVL Pharmaceuticals plc (RVLP) Delisted Director 0 $0.03 $0 $12.40M 2 2023-01-30
OABIW Director 15,871,242 $0.08 $1.32M $0 2 2023-01-05
RVL Pharmaceuticals plc (OSMT) Delisted Director 15,730,864 $1.11 $17.46M $6.25M 2 2020-11-23
ORGO Director 29,840,171 $2.53 $75.50M $116.01M 1 2020-11-19
WideOpenWest, Inc. (WOW) Delisted Director 27,145,193 $5.20 $141.16M $0 3 2019-05-13
LNTH Director 260,501 $102.64 $26.74M -$154.91M 9 2017-09-11
Organogenesis Holdings Inc. (AHPAW) Delisted President and CEO — $0.69 — $0 1 2017-07-07
INCR Director 42,406 $0.92 $39.0K $43.2K 4 2017-05-24
ANGIODYNAMICS INC (ANGO.V) Delisted Director 1,470,401 — — -$103.29M 10 2017-04-14
Organogenesis Holdings Inc. (AHPAU) Delisted President and CEO — $6.16 — $0 1 2016-11-29
Warner Chilcott plc (WCRX) Delisted Director 20,000 — — $304.2K 4 2009-08-07

Recent Filings

41 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2023-09-25 — Notice (144) −670,694 -$60.4K EDGAR
2023-08-24 — Notice (144) −767,515 -$105.8K EDGAR
2023-01-30 RVL Pharmaceuticals plc (RVLP) Delisted Other (J) −1,032,995 $0 EDGAR
2023-01-05 OABIW Grant (A) +373,156 $0 EDGAR
2022-12-05 OABIW Grant (A) — $0 EDGAR
2022-08-09 RVL Pharmaceuticals plc (RVLP) Delisted Buy (P) +8,000,000 $12.40M EDGAR
2020-11-23 RVL Pharmaceuticals plc (OSMT) Delisted Other (J) −4,936,926 $0 EDGAR
2020-11-19 ORGO Buy (P) +35,233,296 $116.01M EDGAR
2020-01-15 RVL Pharmaceuticals plc (OSMT) Delisted Buy (P) +1,250,000 $6.25M EDGAR
2019-05-13 WideOpenWest, Inc. (WOW) Delisted Grant (A) +218,512 $0 EDGAR
Showing 1–10 of 41
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.